Experimental weight loss drugs are being sold online for "research use only"—but many are injecting them at home.

Novo Nordisk just announced Wegovy for $499/month on its direct-to-consumer platform—but is this price cut really a game-changer?

FDA Cracks Down on Compounded Semaglutide, Eli Lilly Slashes Zepbound Prices, and Insurance Struggles Continue

Explore Medicare's groundbreaking decision to negotiate Ozempic pricing in PoundsPunch Periodical 2025.01.

Weight-Loss Drug Wars Heat Up, PBM Reform Stalls, and Insurers Push Back

Biden’s Weight-Loss Drug Proposal Faces Trump-Era Challenges, Ireland’s Crackdown on Counterfeits, and China’s Next-Gen GLP-1 Innovations

New Proposal to Expand Medicare Coverage Raises Questions on Cost and Potential Savings

Caremark, Express Scripts, and OptumRx Face Allegations of Rigging the Rebate System

Medicare’s Lower Drug Premiums, Lilly’s Shortage Supply Resolved While Compounding Pharmacies Still in Play

A Heated Exchange on the Super Star Weight Loss Drugs' Price, Big Pharma and PBM's Finger-Pointing Game

Insurers Raise Premiums or Drop Coverage Due to High Costs of Weight Loss Drugs; FDA Approves New Oral Weight Loss Pill Welcome to...

Commercial Insurance Dominated Weight Loss Prescriptions, Medicare May Target Wegovy for Price Cuts, FDA Reported Eased Drug Shortages

House Bill to Expand Medicare Weight Loss Drug Coverage, The Novo Nordisk CEO to Testify in Senate, Lilly’s Approval in China and More

Weight Loss Drug & Erectile Dysfunction, Eli Lilly’s New Factory, Weight Regain after Stop Using the Drug

Balancing Soaring Costs and Employee Well-being.